United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Swiss National Bank

Swiss National Bank trimmed its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 5.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 125,055 shares of the biotechnology company's stock after selling 7,300 shares during the period. Swiss National Bank owned approximately 0.28% of United Therapeutics worth $44,813,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of UTHR. Thrivent Financial for Lutherans raised its holdings in shares of United Therapeutics by 33.7% during the third quarter. Thrivent Financial for Lutherans now owns 14,332 shares of the biotechnology company's stock worth $5,136,000 after purchasing an additional 3,615 shares during the last quarter. Seizert Capital Partners LLC raised its holdings in shares of United Therapeutics by 59.2% during the third quarter. Seizert Capital Partners LLC now owns 38,906 shares of the biotechnology company's stock worth $13,942,000 after purchasing an additional 14,465 shares during the last quarter. Nicollet Investment Management Inc. raised its holdings in shares of United Therapeutics by 1.1% during the third quarter. Nicollet Investment Management Inc. now owns 5,833 shares of the biotechnology company's stock worth $2,090,000 after purchasing an additional 61 shares during the last quarter. Archer Investment Corp purchased a new position in shares of United Therapeutics during the third quarter worth $283,000. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of United Therapeutics by 20.9% during the third quarter. Oppenheimer & Co. Inc. now owns 6,248 shares of the biotechnology company's stock worth $2,239,000 after purchasing an additional 1,078 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 7,802 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the completion of the transaction, the chief financial officer now owns 3,210 shares in the company, valued at $1,108,766.10. This trade represents a 70.85 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the transaction, the director now owns 5,655 shares of the company's stock, valued at $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,796 shares of company stock worth $40,936,370 in the last 90 days. Corporate insiders own 11.90% of the company's stock.

United Therapeutics Trading Up 1.0 %

UTHR opened at $364.33 on Thursday. The firm has a market capitalization of $16.27 billion, a PE ratio of 16.00, a PEG ratio of 1.05 and a beta of 0.56. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The firm's 50-day moving average price is $363.86 and its 200 day moving average price is $330.33.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's revenue was up 22.9% on a year-over-year basis. During the same period in the previous year, the business posted $5.38 EPS. As a group, analysts predict that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on UTHR shares. Argus raised their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. TD Cowen lifted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a report on Monday, October 21st. The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a report on Friday, November 1st. Jefferies Financial Group lifted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Finally, Bank of America cut their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.